StreetInsider.com News Articles

CAMP4 Therapeutics (CAMP) Reiterated at Overweight by Cantor Fitzgerald After Analyst Day

Tue, 29 Sep 2026 07:18:53 -0400

Cantor Fitzgerald analyst Steve Seedhouse reiterated an Overweight rating and $7.00 price target on CAMP4 Therapeutics Corp (NASDAQ: CAMP).

The analyst commented, "CAMP4 hosted an analyst event that offered new details on 1) Phase 1/2 clinical trial in SYNGAP (initiating 4Q26 - details below), and 2) Early pipeline update (disclosed next program targeting SHANK3 for Phelan-McDermid Syndrome). Outside experts on the call also reinforced the SYNGAP unmet need / pent-up demand for a new therapeutic. CAMP is already pre-screening patients (and per patient advocacy group CEO on the call today (09/28), there is tremendous excitement to enroll) and trial will begin

CAMP4 Therapeutics Corp (CAMP) PT Lowered to $6 at Chardan

Tue, 29 Sep 2026 06:10:22 -0400

Chardan analyst Keay Nakae lowered the price target on CAMP4 Therapeutics Corp (NASDAQ: CAMP) to $6.00 (from $6.50) while maintaining a Buy rating.

Camp4 Therapeutics gets UK approval for SYNGAP1 drug trial

Thu, 10 Sep 2026 07:33:39 -0400

Camp4 Therapeutics Corporation (Nasdaq: CAMP) has received authorization from the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) to include UK sites in its Phase 1/2 clinical trial of CMP-002, an investigational therapeutic candidate for SYNGAP1-related disorder.

The authorization follows clearances received in July 2026 from Australia's Therapeutic Goods Administration and local Human Research Ethics Committee, as well as Argentina's ANMAT. The company has also submitted regulatory filings in the European Union, which remain under review. Camp4 said it expects to initiate the trial in the fourth quarter of 2026.

CMP-002 is an antisense oligonucleotide (ASO) designed to bind to a

CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder

Thu, 10 Sep 2026 07:33:00 -0400

Authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) builds on CAMP4’s recent clearances to initiate first-in-human studies for CMP-002 in Australia and Argentina

Company anticipates initiation of the clinical trial in 4Q 2026

WATERTOWN, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced the company

CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder

Thu, 10 Sep 2026 07:33:00 -0400

Company anticipates initiation of the clinical trial in 4Q 2026

CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026

Tue, 08 Sep 2026 16:05:00 -0400

WATERTOWN, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, will host a virtual Analyst Day on Monday, September 28, 2026 from 12:00 – 1:30 PM ET featuring presentations and Q&A led by CAMP4’s executive leadership team and participation from patient advocates and a leading KOL. To register, click here.

Live webcasts can be accessed

CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026

Tue, 08 Sep 2026 16:05:00 -0400

Live webcasts can be accessed

CAMP4 to Participate in Upcoming Investor Conferences

Tue, 01 Sep 2026 16:05:00 -0400

WATERTOWN, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that the Company will participate in the following upcoming investor conferences:

Wells Fargo 21st Annual Healthcare Conference

Format:

CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that the Company will participate in the following upcoming investor conferences:

Wells Fargo 21st Annual Healthcare Conference

Format:

click here.

CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights

Thu, 13 Aug 2026 16:05:00 -0400

Secured regulatory clearance in two jurisdictions to initiate first-in-human Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP-1 related disorder; trial initiation anticipated in the fourth quarter of this year.

Received $50.1 million from fully subscribed second closing of private placement initially announced September 2025. Cash runway extended through the end of 2028.

WATERTOWN, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein

CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights

Thu, 13 Aug 2026 16:05:00 -0400

Received $50.1 million from fully subscribed second closing of private placement initially announced September 2025. Cash runway extended through the end of 2028.

Form 4 Camp4 Therapeutics Corp For: Aug 03 Filed by: 5AM Ventures VII, L.P.

Wed, 05 Aug 2026 17:40:00 -0400

si-local-file:///var/storage/secattach/20260805/26876181.html

Form 4 Camp4 Therapeutics Corp For: Aug 03 Filed by: Schwab Andrew J.

Wed, 05 Aug 2026 17:29:00 -0400

si-local-file:///var/storage/secattach/20260805/26876121.html

Form 4 Camp4 Therapeutics Corp For: Aug 03 Filed by: Young Richard A

Wed, 05 Aug 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260805/26875815.html

Form 4 Camp4 Therapeutics Corp For: Aug 03 Filed by: Maricich Yuri

Wed, 05 Aug 2026 17:09:00 -0400

si-local-file:///var/storage/secattach/20260805/26875801.html

Form 4 Camp4 Therapeutics Corp For: Aug 03 Filed by: Gold Kelly

Wed, 05 Aug 2026 17:08:00 -0400

si-local-file:///var/storage/secattach/20260805/26875789.html

Form 4 Camp4 Therapeutics Corp For: Aug 03 Filed by: Mandel-Brehm Josh

Wed, 05 Aug 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260805/26875773.html

Camp4 Therapeutics closes second tranche of $100M private placement

Tue, 04 Aug 2026 07:00:27 -0400

Camp4 Therapeutics Corporation (Nasdaq: CAMP) announced the closing of the second tranche of a previously announced private placement, raising approximately $50.1 million in gross proceeds.

The second closing involved the issuance of 10,756,498 shares of common stock priced at $1.53 per share, 39,306 shares priced at $1.65 to certain directors, employees, and consultants, and 21,925,368 pre-funded warrants at $1.5299 each. The securities purchase agreement was originally dated September 9, 2025.

The company said it intends to use the net proceeds to advance CMP-002, its lead investigational antisense oligonucleotide therapeutic candidate targeting SYNGAP1-related disorder. Camp4 recently received clearance from Australia's Therapeutic Goods Administration

CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement

Tue, 04 Aug 2026 07:00:00 -0400

Proceeds of $50.1 million will be used to support the Company’s advancement of CMP-002 for the treatment of SYNGAP1-related disorder

CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced the closing of the second tranche of its previously announced private placement pursuant to a securities purchase agreement, dated September 9, 2025, with certain institutional

CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement

Tue, 04 Aug 2026 07:00:00 -0400

Proceeds of $50.1 million will be used to support the Company’s advancement of CMP-002 for the treatment of SYNGAP1-related disorder